Document Detail

Molecular Pathology in Cancer Therapeutics: where are we now and where are we going? Animal modeling of cancer pathology and studying tumor response to therapy.
MedLine Citation:
PMID:  22974396     Owner:  NLM     Status:  Publisher    
Animal models of human cancer have evolved in attempts to capture the complexity of the human disease. They encompass two broad types of model, namely those in which the tumor arises in situ and those in which cancer cells or tissue are transplanted. Currently human tumor xenografts are the most widely used model to help predict antitumor efficacy in a preclinical setting and xenograft results for certain disease types such as ovarian cancer and non-small cell lung cancer correlate well with clinical activity if the models are used under appropriate conditions. The genetically engineered mouse (GEM) models allow study of the effects of targeted inhibitors against defined molecular targets. These are becoming increasingly sophisticated to recapitulate the progression of tissue-specific molecular changes found within individual cancers. Non-germline GEM models possess the ability to study the impact of specific cancer genes without some of the limitations inherent in traditional GEM models. While rodents, particularly mice, have been the animal host most frequently used, there is increasing recognition of the value of using larger species especially dogs in the veterinary oncology setting. These have successfully modelled aspects of selected human cancers such as osteosarcoma, GIST and prostate cancer. Individually, these models have relative strengths and weaknesses in mimicking the human disease and appropriately reflecting its cellular and molecular pathology. This review will seek to address where these models can be best used to help predict response to therapeutics.
Simon P Langdon
Related Documents :
23092636 - The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate...
24569466 - Diabetes and prognosis in older persons with colorectal cancer.
24357736 - Lung cancer screening: advantages, controversies, and applications.
23400486 - Ncab gains new members.
23326146 - A meta-analysis of the effects of energy intake on risk of digestive cancers.
23658296 - Two is better than one: combining igf1r and mek blockade as a promising novel treatment...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-07
Journal Detail:
Title:  Current drug targets     Volume:  -     ISSN:  1873-5592     ISO Abbreviation:  Curr Drug Targets     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960531     Medline TA:  Curr Drug Targets     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Breakthrough Research Unit and Division of Pathology, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road South Edinburgh, EH4 2XU, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.
Next Document:  Molecular Pathology in Neurodegenerative Diseases.